Infrastructure, agriculture, and workforce are the pillars for Bluestem’s commercial scale up of our bio-based chemical platform. These facets of industrial biotechnology are prominently found in the Midwest, and Bluestem is focused on maximizing their future potential
We believe that public & private partnerships integrating government, academia, and industry will accelerate our shared path to commercial success of our decarbonized chemical platform.
Infrastructure, agriculture, and workforce are the pillars for Bluestem’s commercial scale up of our bio-based chemical platform. These facets of industrial biotechnology are prominently found in the Midwest, and Bluestem is focused on maximizing their future potential
We believe that public & private partnerships integrating government, academia, and industry will accelerate our shared path to commercial success of our decarbonized chemical platform.
A multi-disciplinary entrepreneur with leadership experience across science, technology, operations. Most recently, Tyler served as SVP of Science & Technology at Green Plains and prior to that co-founded Cannalysis Labs. Tyler graduated from San Diego State with a BS in Biology.
Sarang is a highly driven PhD candidate at the University of Illinois Urbana- Champaign where he designs, simulates, and evaluates (via techno- economic analysis and life cycle assessment) biorefineries to characterize their financial viability and environmental sustainability and set development targets in projects funded by DOE and BioMADE. With Bluestem, he leverages his expertise to develop tools to design and evaluate biorefineries for over 200 biochemical pathways, act as key personnel in contributing to grant proposals, and provide regular inputs to help prioritize research and development.
Kate previously served as Director of Platform Operations at Think Bioscience. Prior to that, Kate spent 5 years building high throughput laboratory operations at Demetrix. Kate started her career in industrial biotechnology at Amyris, working in strain engineering and automated operations. Kate holds a BS in Chemical Engineering from the University of Notre Dame, and a PhD in Chemical Engineering from The University of Texas at Austin, where her research focused on metabolic engineering and building of genetic tools in yeast.
Billy Hagstrom previously served as Executive Vice President of Strategy & Development for Green Plains, Inc.. Prior to moving to Omaha in 2021, Billy served as Chief Executive Officer of Cannalysis. Previously, Billy was a Managing Director at Highbridge Capital Management. Billy started in investment banking at J.P. Morgan focused on Natural Resources & Infrastructure. Billy earned his BA in Economics from Northwestern University.
Youngnyun was trained as a domain expert in microbial molecular biology, metabolic engineering, and fermentation of biochemicals. He has worked at Zymergen and at Amyris for more than a decade. His strong scientific background in microbial synthetic biology and physiology plays a key role at OLAB. He received his Ph.D. from the University of Florida at Gainesville, FL
Cameron Rylance has a passion for environmental sustainability and people. After receiving his Masters of Biomedical Engineering from Clemson University, Cameron combined his passions with his entrepreneurial spirit to develop more sustainable solutions for single-use medical device kits. While at Clemson, Cameron’s research focused on genome editing of mammalian cells through viral transcription. Cameron earned his BS in Bioengineering from Clemson University.
Mark Simon enjoys bringing novel solutions to long standing problems. Mark received his PhD from MIT, where he was the principal inventor of the Automated Fast Flow Peptide Synthesis platform, accelerating chemical peptide synthesis nearly 100 fold while substantially improving yield and purity. Upon graduation, Mark spent 3 years at Ginkgo Bioworks, developing experience in biochemical pathway design.
Jared Wenger has spent over 10 years in the biotech industry, most recently leading Technical Operations for a vaccine startup in Nebraska. Prior to moving to Nebraska, Jared spent 4 years at Zymergen, initially developing genetic tools for bacterial and yeast strain manufacturing pipelines, and ultimately leading process engineering and continuous improvement efforts across Build and Test capabilities. Jared started his career as a strain engineer at Amyris, after receiving his Ph.D. in Genetics from Stanford and B.S. in Biological Sciences from Carnegie Mellon.
A multi-disciplinary entrepreneur with leadership experience across science, technology, operations. Most recently, Tyler served as SVP of Science & Technology at Green Plains and prior to that co-founded Cannalysis Labs. Tyler graduated from San Diego State with a BS in Biology.
Sarang is a highly driven PhD candidate at the University of Illinois Urbana- Champaign where he designs, simulates, and evaluates (via techno- economic analysis and life cycle assessment) biorefineries to characterize their financial viability and environmental sustainability and set development targets in projects funded by DOE and BioMADE. With Bluestem, he leverages his expertise to develop tools to design and evaluate biorefineries for over 200 biochemical pathways, act as key personnel in contributing to grant proposals, and provide regular inputs to help prioritize research and development.
Kate previously served as Director of Platform Operations at Think Bioscience. Prior to that, Kate spent 5 years building high throughput laboratory operations at Demetrix. Kate started her career in industrial biotechnology at Amyris, working in strain engineering and automated operations. Kate holds a BS in Chemical Engineering from the University of Notre Dame, and a PhD in Chemical Engineering from The University of Texas at Austin, where her research focused on metabolic engineering and building of genetic tools in yeast.
Billy Hagstrom previously served as Executive Vice President of Strategy & Development for Green Plains, Inc.. Prior to moving to Omaha in 2021, Billy served as Chief Executive Officer of Cannalysis. Previously, Billy was a Managing Director at Highbridge Capital Management. Billy started in investment banking at J.P. Morgan focused on Natural Resources & Infrastructure. Billy earned his BA in Economics from Northwestern University.
Youngnyun was trained as a domain expert in microbial molecular biology, metabolic engineering, and fermentation of biochemicals. He has worked at Zymergen and at Amyris for more than a decade. His strong scientific background in microbial synthetic biology and physiology plays a key role at OLAB. He received his Ph.D. from the University of Florida at Gainesville, FL
Cameron Rylance has a passion for environmental sustainability and people. After receiving his Masters of Biomedical Engineering from Clemson University, Cameron combined his passions with his entrepreneurial spirit to develop more sustainable solutions for single-use medical device kits. While at Clemson, Cameron’s research focused on genome editing of mammalian cells through viral transcription. Cameron earned his BS in Bioengineering from Clemson University.
Mark Simon enjoys bringing novel solutions to long standing problems. Mark received his PhD from MIT, where he was the principal inventor of the Automated Fast Flow Peptide Synthesis platform, accelerating chemical peptide synthesis nearly 100 fold while substantially improving yield and purity. Upon graduation, Mark spent 3 years at Ginkgo Bioworks, developing experience in biochemical pathway design.
Jared Wenger has spent over 10 years in the biotech industry, most recently leading Technical Operations for a vaccine startup in Nebraska. Prior to moving to Nebraska, Jared spent 4 years at Zymergen, initially developing genetic tools for bacterial and yeast strain manufacturing pipelines, and ultimately leading process engineering and continuous improvement efforts across Build and Test capabilities. Jared started his career as a strain engineer at Amyris, after receiving his Ph.D. in Genetics from Stanford and B.S. in Biological Sciences from Carnegie Mellon.
Gregg is an expert in downstream processing and product “upgrading” through chemistry (including acrylics)
Hugo is an expert in process development, microbial physiology, and thinking anaerobically.
Cathy has invented and commercialized yeast biocatalysts for the production of biofuels and renewable chemicals for over 20 years Two key examples include the low pH lactic acid-producing yeast used by NatureWorks & Cargill for the production of PLA and the isobutanol-producing yeast used by Gevo. She earned her [B.S. in Biology from the University of Nebraska-Lincoln and] her Ph.D. in Molecular Biology & Genetics from the University of Minnesota.
_logo.svg.png){kind=logo}
Alex Greenbaum is Partner at EQT Group, a $100 billion private equity group, where Alex is focused on infrastructure for North America. Previously, Alex was Head of North America Infrastructure for GIC (Govt of Singapore).
Kristy has 20 years of experience in the field of synthetic biology focusing on yeast metabolic engineering for the production of small molecules while earning a Ph.D. in chemical engineering at Caltech. She is currently a co-founder and CSO at Antheia.
Ton is a world renowned bioprocess engineer, microbial physiologist, and visionary in anaerobic fermentation. He is department head for Industrial Biotechnology at KTH (Stockholm). He was formerly at TUDelft and Tate & Lyle.
Kevin is an +25yr leader with track record of bottom-line results in commercial, R&D, and operations leadership roles. History of taking on challenging high-risk assignments
Neil has proven experience in developing and commercializing novel climate-impacting technologies, from concept through implementation, with leading network in climate and VC
Matt is the CEO of Navigator CO2, and a thought leader in transitional energy, and midwest infrastructure. Navigator is a Blackrock-backed company building the largest carbon sequestration network in the Midwest.
Todd has been a leader in both private and public roles. Previously as Chief Science Officer of ADM, and also running Business Development of New Chemicals at PNNL, a US national laboratory.
Bluestem is excited to offer a remote-first working model. Team members can work primarily remotely. Conditions permitting, teams will meet in person every quarter or two at Bluestem’s HQ, in Omaha, NE. We believe this balanced, flexible approach gives our team members the best of both worlds: plenty of focus time along with in-person collaboration that fosters trust, unlocks creativity, and further fuels innovation.
